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Efficacy and safety of transcatheter 
closure in adults with large or small  
atrial septal defects
Matthias R. Meyer1, David J. Kurz1, Alain M. Bernheim1, Oliver Kretschmar2 and Franz R. Eberli1*
Abstract 
Background: In most patients with secundum atrial septal defects (ASD), transcatheter closure is the preferred treat-
ment strategy, but whether device size affects clinical outcomes is unknown. We sought to study the efficacy and 
safety of large closure devices compared to the use of smaller devices.
Methods: Using a single-center, prospective registry of adult patients undergoing transcatheter ASD closure, 
patients receiving a large closure device (waist diameter ≥25 mm, n = 41) were compared to patients receiv-
ing smaller devices (waist diameter ≤24 mm, n = 66). We analyzed pre-interventional clinical, hemodynamic and 
echocardiographic data, interventional success and complication rates, and 6-month clinical and echocardiographic 
outcomes. The primary efficacy outcome was successful ASD closure achieved by a single procedure and confirmed 
by lack of a significant residual shunt at 6 months. The primary safety outcome was a composite of device emboliza-
tion, major bleeding, and new-onset atrial arrhythmia occurring within 6 months.
Results: Transcatheter ASD closure using large devices was successful in 90 % compared to 97 % of patients receiv-
ing smaller devices as defined by the primary efficacy outcome (p = 0.20). The primary safety outcome occurred 
in 4 patients of the large and 6 patients of the small device group, resulting in an event-free rate of 90 and 91 %, 
respectively (p = 0.89). Similar significant symptomatic improvement was observed in both treatment groups after 
6 months, indicated by a 50 % increase in the fraction of patients in NYHA class I (p < 0.0001 vs. baseline).
Conclusions: Transcatheter closure in this cohort of patients with large or small ASD was effective with similar com-
plication rates during short-term follow-up irrespective of the size of the implanted device.
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Background
Atrial septal defects (ASD) are the most common congen-
ital heart defects diagnosed in adults. If left unrepaired, 
an ASD may lead to right ventricular volume overload, 
pulmonary hypercirculation, and congestive heart fail-
ure (Warnes et al. 2008; Baumgartner et al. 2010). Since 
the first transcatheter device closure of an ASD was per-
formed in 1976 (King et al. 1976), it has become the pre-
ferred treatment strategy for isolated secundum ASD due 
to its high efficacy and low complication rate compared 
to surgical repair (Du et  al. 2002; Thomson et  al. 2002; 
Fischer et al. 2003; Butera et al. 2006), and is now widely 
used in both children and adults (Baumgartner et  al. 
2010; Warnes et al. 2008).
Rarely, transcatheter ASD closure may lead to major 
complications, including perforation of the atrial wall, 
device embolization, and atrial arrhythmia (Amin 
et  al. 2004; Butera et  al. 2006; Du et  al. 2002; Fischer 
et  al. 2003; Majunke et  al. 2009; Thomson et  al. 2002). 
Although these adverse events occur in less than 2 % of 
patients, complication rates may increase if large devices 
are needed for defect closure (Lopez et  al. 2005; Butera 
et  al. 2008). In fact, successful device deployment may 
become technically challenging with less residual tissue 
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surrounding a large ASD (Butera et al. 2008; Guan et al. 
2008), and smaller rims as well as the use of large devices 
may increase the risk of atrial perforation (Amin et  al. 
2004). In addition, transient atrioventricular (AV) block 
has been reported after closure of large ASD (Suda et al. 
2004; Guan et al. 2008; Marini et al. 2012).
Despite concerns about the safety of large closure 
devices (Amin et al. 2004; Guan et al. 2008; Lopez et al. 
2005), a systematic comparison to the use of smaller 
devices has not yet been reported. Furthermore, cur-
rent guidelines do not discuss the potentially increased 
risk related to transcatheter closure of large as opposed 
to smaller ASD (Warnes et  al. 2008; Baumgartner et  al. 
2010). The aim of the present study, therefore, was to 
assess the efficacy and safety of transcatheter ASD clo-
sure in patients requiring a large device compared 
to patients in whom the use of smaller devices was 
appropriate.
Results
Patient characteristics
A total of 107 patients undergoing transcatheter ASD 
closure were followed through 6 months and analyzed; of 
these, 41 (38 %) received a large and 66 (62 %) received a 
small closure device. Clinical characteristics prior to ASD 
closure are given in Table  1. Patients were between 19 
and 82 years of age (mean 48.9 ± 15.6 years), with 57 % 
being females. 39  % of patients reported symptoms of 
heart failure according to New York Heart Association 
(NYHA) functional class II or greater, with no difference 
between groups. Rates of atrial fibrillation were similar 
before implantation of large or small devices (17 and 9 %, 
respectively, p  =  0.24). The presence of hypertension, 
diabetes, dyslipidemia and history of stroke or transient 
ischemic attack (TIA) also did not differ significantly 
between groups.
ASD size and hemodynamic severity
Median ASD size was 27 mm in patients receiving large 
and 19  mm in patients receiving small ASD closure 
devices, with no difference in the rate of multiple defects 
(Table 1). Median size of implanted devices was 30 and 
20 mm, respectively (Table 1). Prior to ASD closure, com-
plete invasive hemodynamics and oximetry data were 
obtained in 49 patients (Table 2). Patients with large ASD 
had greater left–right shunt (59 vs. 35 %, p = 0.0002) and 
pulmonary to systemic flow (Qp/Qs) ratio (2.13 vs. 1.50, 
p  =  0.03). Hemodynamic consequences of large ASD’s 
were further evidenced by significantly higher right atrial, 
right ventricular, systolic and mean pulmonary artery as 
well as pulmonary capillary wedge pressures compared to 
patients with small ASD (Table 2).
Table 1 Baseline characteristics of patients undergoing transcatheter ASD closure
Data are given as mean ± standard deviation or median (inter-quartile range) where appropriate. p values were calculated based on statistical comparison of the 
large and small device groups
NYHA New York Heart Association functional class, ECG electrocardiogram, TIA transient ischemic attack
All patients (n = 107) Large device group (n = 41) Small device group (n = 66) p value
Demographic characteristics
 Age (years) 48.9 ± 15.6 48.9 ± 14.7 48.9 ± 16.3 0.99
 Gender (female), n (%) 61 (57) 22 (54) 39 (59) 0.69
Medical history, n (%)
 NYHA I 65 (61) 26 (63) 39 (59) 0.69
 NYHA II 32 (30) 11 (27) 21 (32) 0.67
 NYHA III 9 (8) 3 (7) 6 (9) 1.00
 NYHA IV 1 (1) 1 (2) 0 (0) 0.38
 Atrial fibrillation 13 (12) 7 (17) 6 (9) 0.24
 Right axis deviation on ECG 11 (9) 8 (20) 2 (3) 0.007
 Arterial hypertension 26 (24) 10 (24) 16 (24) 1.00
 Diabetes mellitus 4 (4) 3 (7) 1 (2) 0.16
 Dyslipidemia 20 (19) 6 (15) 14 (21) 0.45
 Stroke/TIA 23 (21) 5 (12) 18 (27) 0.09
ASD characteristics
 Defect size (mm) 24 (16, 27) 27 (24, 34) 19 (14, 24) <0.0001
 Multiple defects, n (%) 9 (8) 3 (7) 6 (9) 1.00
 Device size (mm) 24 (18, 28) 30 (26, 34) 20 (16, 24) <0.0001
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Efficacy of transcatheter ASD closure
Successful transcatheter ASD closure was achieved with 
a single procedure and confirmed by lack of a significant 
shunt detectable by transesophageal echocardiography 
(TEE) at 6-month follow-up in 90 and 97  % of patients 
receiving large and small devices, respectively, with no 
statistical difference between groups (p = 0.20, Table 3). 
When only patients receiving Amplatzer devices were 
included in the analysis, 92 and 97 % of large and small 
ASD were successfully closed, respectively (p  =  0.37). 
Significant shunts were present following implanta-
tion of 3 large and 1 small closure devices (p  =  0.16); 
two patients with large ASD successfully underwent a 
second transcatheter procedure, while the remaining 
two patients are being followed clinically due to lack of 
hemodynamic significance based on repeat invasive 
assessment or due to concomitant medical conditions. 
Complete endothelialization of ASD closure devices as 
confirmed by lack of any residual shunt detected dur-
ing follow-up TEE was not significantly more frequent 
in patients receiving small devices (82 vs. 66  % in the 
large device group, p  =  0.07). One patient in the large 
device group was referred for surgical ASD closure due 
to device embolization, while a repeat transcatheter ASD 
closure was performed in one patient in the small device 
group after distal embolization of the initially implanted 
device. One patient in each group received 2 devices dur-
ing the first intervention in order to achieve complete 
ASD closure.
Six months after ASD closure, similar symptomatic 
improvement was observed in both treatment groups 
(Fig. 1). Compared to baseline functional status, the frac-
tion of patients in NYHA class I increased from 63 to 
95 % and from 59 to 91 % after implantation of large and 
small devices, respectively (50 % increase, p < 0.0001 vs. 
baseline). The remaining 5 and 9  % of patients, respec-
tively, were in NYHA class II after ASD closure. Func-
tional status both before the intervention and 6 months 
thereafter was not different between groups.
Safety of transcatheter ASD closure
The primary safety outcome at 6-month follow-up, a 
composite of device embolization, new-onset atrial 
arrhythmia, and major bleeding, did not differ between 
patients receiving large or small devices (10 vs. 9  %, 
p = 1.0, Table 4). Similarly, there was no difference in the 
Table 2 Shunt calculations and invasive hemodynamics before ASD closure
Shunt calculations were performed based on oximetric data using the Fick formula (Miller et al. 1974). Data are given as median (inter-quartile range)
Qp:Qs pulmonary to systemic flow ratio, RA right atrium, RV right ventricle, PA pulmonary artery, PCWP pulmonary capillary wedge pressure
All patients (n = 49) Large device group (n = 19) Small device group (n = 30) p value
Shunt calculations
 Qp:Qs 1.57 (1.37, 2.32) 2.13 (1.49, 2.87) 1.50 (1.22, 2.00) 0.03
 Left–right shunt (%) 40 (31, 59) 59 (46, 67) 35 (27, 43) 0.0002
 Right–left shunt (%) 4 (0, 8) 6 (1, 10) 4 (0, 7) 0.20
Invasive hemodynamics (mmHg)
 RA mean pressure 6 (4, 9) 7 (5, 11) 5 (3, 8) 0.03
 RV end-diastolic pressure 8 (6, 10) 9 (8, 12) 6 (5, 8) 0.002
 PA systolic pressure 32 (27, 37) 35 (30, 45) 29 (25, 34) 0.004
 PA diastolic pressure 11 (8, 15) 11 (7, 16) 11 (8, 15) 0.56
 PA mean pressure 19 (15, 24) 24 (16, 28) 18 (14, 22) 0.03
 PCWP 11 (7, 15) 14 (11, 16) 9 (7, 13) 0.04
 Transpulmonary gradient 9 (5, 11) 10 (8, 11) 9 (4, 11) 0.27
Table 3 Efficacy outcomes 6 months after transcatheter ASD closure
The primary outcome was defined as successful transcatheter ASD closure achieved with a single procedure and confirmed by lack of a significant shunt detectable by 
TEE at 6-month follow-up as specified in the "Methods" section
All patients (n = 107) Large device group (n = 41) Small device group (n = 66) p value
Primary efficacy outcome, n (%) 99 (93) 37 (90) 64 (97) 0.20
Secondary efficacy outcomes, n (%)
 Repeat transcatheter closure 3 (3) 2 (5) 1 (2) 0.56
 Referral for surgical closure 1 (1) 1 (2) 0 (0) 0.38
 Any residual shunt 26 (24) 14 (34) 12 (18) 0.07
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corresponding event-free rates based on Kaplan–Meier 
estimates between groups (90 vs. 91 %, p = 0.89, Fig. 2). 
In addition, the primary safety outcome was similar when 
only patients receiving Amplatzer devices were included 
in the analysis (11 vs. 10  %, respectively, p =  1.0). In 1 
patient, closure of a large ASD (defect size 34  mm) 
requiring implantation of 2 devices resulted in embo-
lization of the second device into the pulmonary artery. 
This patient underwent urgent surgical device removal 
and ASD patch closure. Furthermore, 1 patient presented 
with acute limb ischemia due to device embolization 
into the aortic bifurcation 143 days after implantation of 
a small closure device; this patient underwent surgical 
device removal followed by a successful repeat transcath-
eter ASD closure.
Intervention-related major bleeding complications 
(bleeding Type 3a according to the Bleeding Academic 
Research Consortium (BARC) classification (Mehran 
et  al. 2011) at the access site in two patients, and tran-
sient hemoptysis in one patient due to guidewire (diam-
eter, 0.018 in.)-related perforation of the left upper 
pulmonary vein used with a Solysafe device) were 
observed after implantation of 3 small closure devices, 
whereas no bleeding complications occurred in the large 
device group (p = 0.28, Table 4). There was no difference 
between the large device and the small device groups 
with regard to fluoroscopy time (15 (11, 20) vs. 14 (11, 
23) min), amount of contrast medium used (185 (144, 
235) vs. 150 (110, 215) mL), and length of hospital stay 
(2 (2, 2) vs. 2 (2, 2) days, all data expressed as median and 
inter-quartile range).
During follow-up, 5 % of patients developed new-onset 
atrial flutter or fibrillation following ASD closure, with 
no difference between groups (p  =  0.37, Table  4). One 
patient with a large ASD died during follow-up of a cause 
unrelated to the closure procedure.
Discussion
Transcatheter closure is considered first-line therapy 
over surgical closure for patients with morphologically 
suitable secundum ASD (Warnes et  al. 2008; Baum-
gartner et al. 2010). In particular, defect closure should be 
Fig. 1 Symptomatic status according to NYHA classification at base-
line (Pre) and 6 months after (Post) transcatheter ASD closure with 
large or small devices. NYHA New York Heart Association functional 
class
Table 4 Safety outcomes 6 months after transcatheter ASD closure
The primary safety outcome at 6-month follow-up was a composite of device embolization, new-onset atrial arrhythmia, and major bleeding classified as Type 2 or 
greater according to the BARC definition
All patients (n = 107) Large device group (n = 41) Small device group (n = 66) p value
Primary safety outcome, n (%) 10 (9) 4 (10) 6 (9) 1.00
Secondary safety outcomes, n (%)
 Device embolization 2 (2) 1 (2) 1 (2) 1.00
 New-onset atrial arrhythmia 5 (5) 3 (7) 2 (3) 0.37
 Major bleeding 3 (3) 0 (0) 3 (5) 0.28
 Death 1 (1) 1 (2) 0 (0) 0.38
Fig. 2 Event-free rate through 6 months after transcatheter ASD 
closure. Shown are Kaplan–Meier estimates for patients who received 
a large or small ASD closure device. Adverse events included device 
embolization, new-onset atrial arrhythmia, and major bleeding 
graded as Type 2 or greater according to the BARC definition
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attempted if there is evidence for right ventricular volume 
overload (Warnes et  al. 2008; Baumgartner et  al. 2010). 
However, current guidelines do not take into account 
whether transcatheter closure of large, hemodynami-
cally more significant ASD may pose an increased risk 
compared to device closure of smaller defects (Warnes 
et al. 2008; Baumgartner et al. 2010). Here, based on the 
first systematic analysis of a cohort of adult patients, we 
report that implantation of large ASD closure devices is 
effective with similar complication rates at implantation 
and through short-term follow-up at 6  months when 
compared with the use of small devices.
The Amplatzer family of closure devices is widely 
used for transcatheter ASD therapy. In a pivotal multi-
center trial including 596 patients, the Amplatzer Septal 
Occluder revealed equivalent success rates compared 
to surgical repair (Du et  al. 2002). However, complica-
tion rates were lower and the length of hospital stay 
was shorter in the transcatheter closure group (Du et al. 
2002). Subsequent studies have confirmed the safety and 
efficacy of the device (Thomson et al. 2002; Fischer et al. 
2003; Majunke et al. 2009). In the present study, the great 
majority of patients (93  %) received Amplatzer devices, 
and we experienced similar high success and low adverse 
event rates, including device embolism, new-onset 
atrial arrhythmia, and major bleeding complications as 
reported previously (Du et al. 2002; Thomson et al. 2002; 
Fischer et al. 2003; Spies et al. 2008; Humenberger et al. 
2011; Majunke et al. 2009).
Currently, devices for closure of defects up to 40  mm 
are available, although no systematic comparison 
between the use of large and small devices has yet been 
performed. Low complication rates following closure of 
large ASD (median device to septal length ratio: 0.95) in 
51 children have been reported (Marini et al. 2012), and 
there are small series of successful use of Amplatzer Sep-
tal Occluders with a waist diameter ≥30  mm in adults 
(Lopez et al. 2005; Guan et al. 2008). However, concerns 
about the safety of large devices remain (Lopez et  al. 
2005). In particular, the most feared complications, such 
as device embolization and atrial perforation, might be 
associated with device size (Amin et al. 2004; Guan et al. 
2008; Lopez et  al. 2005). Smaller rims surrounding a 
large defect may technically complicate successful device 
placement thus increasing the risk of embolization (Guan 
et  al. 2008). In our series, two cases of device emboli-
zation occurred, one each in the large and small device 
group. Furthermore, deficient anterior–superior rims of 
large ASD may increase the chance of contact between 
the device and the atrial wall, particularly in case of 
device oversizing, which may result in atrial perforation 
(Amin et al. 2004). Most atrial perforations occur within 
the first 3 months after device implantation (Amin et al. 
2004), and have also been reported after implantation 
of small closure devices (Amin et al. 2004; Taggart et al. 
2011). In our study, we recorded no evidence of atrial 
erosion at 6  month follow-up, but obviously, we cannot 
address the long-term safety of large compared to small 
devices. Since late atrial perforations have been described 
(Taggart et al. 2011; Herren et al. 2015), longer follow-up 
studies would be desirable.
Major bleeding complications related to the closure 
procedure did not differ between groups. In line with a 
previous study (Spies et al. 2008), the rate of new-onset 
atrial arrhythmia during follow-up was also unrelated to 
device size. In contrast to others (Suda et al. 2004; Guan 
et al. 2008; Marini et al. 2012), we observed no AV block 
following the procedure. Overall, this resulted in similar 
event-free rates in the large and small device group.
In addition to the similar safety outcomes between 
groups, we observed no difference with regard to suc-
cessful transcatheter ASD closure achieved by a single 
procedure and confirmed by lack of a significant shunt 
detectable by TEE at 6-month follow-up. Initial trivial 
shunting across the membrane of the occluding device 
is common and typically closes after full endothelializa-
tion of the surface, which was complete within weeks 
in experimental studies (Lock et  al. 1989) but may take 
longer in some patients (Greutmann et  al. 2009; Chen 
et  al. 2011). Although the degree of endothelialization 
may depend on device diameter (Greutmann et al. 2009), 
we observed no significant difference in residual shunting 
following implantation of large or small closure devices. 
Significant shunting following device implantation was 
rare, but slightly more common in patients with large 
ASD, although this did not reach statistical significance. 
However, large residual shunts in two patients with a 
large closure device were successfully treated with a sec-
ond procedure.
In our study, about 40  % of patients reported symp-
toms of heart failure pre-interventionally. Interestingly, 
the presence of symptoms was not related to defect size, 
despite the greater hemodynamic severity shown in the 
large closure device group. Both treatment groups expe-
rienced similar and highly effective symptom improve-
ment after the intervention. However, symptoms 
commonly aggravate with age, even in the presence of 
smaller defects (Humenberger et  al. 2011). This may be 
the result of age-dependent diastolic dysfunction (Red-
field et al. 2003) or ASD-related impairment of left ven-
tricular compliance (Booth et al. 1988) and thus may not 
necessarily be related to the size of the ASD.
The main limitations of this study are inherent to its 
registry design and the relatively small patient number 
with limited power to detect subtle differences in the rate 
of rare, but possibly serious adverse events. Given that 
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the efficacy outcomes and some of the safety outcomes 
show a trend in favor of the small device group, a larger 
population or meta analysis would be required to dem-
onstrate potentially significant, albeit small effects. An 
additional bias may represent that 5 patients (4 %) in our 
study were lost to follow-up. Moreover, Solysafe septal 
occluders were implanted in 11 patients before an urgent 
safety notice was issued by the manufacturer (Kretsch-
mar et  al. 2010; Knirsch et  al. 2011). These patients are 
being followed by fluoroscopy (Knirsch et  al. 2011). In 
line with the incidence reported by others (Gielen et al. 
2012), one wire fracture was diagnosed 2½ years after 
implantation. No clinical complication has yet resulted in 
that patient.
Conclusions
The present study is the first systematic analysis on the 
use of large compared to small devices for transcatheter 
ASD closure, a procedure widely performed in adults. In 
our experience, transcatheter ASD closure using large 
or small devices is successful and effective with similar 
complication rates during implantation and short-term 
follow-up. Provided that sufficient residual septal tissue 
remains for safe anchorage of the closure device, large 
ASD can safely be closed by the transcatheter approach.
Methods
Patients
Between February 2002 and October 2013, 112 adult 
patients undergoing transcatheter closure of secundum 
ASD at the Triemli City Hospital, Zurich, Switzerland, 
were included in a prospective registry. Indications for 
closure included dilation of right heart chambers, a left–
right shunt with a Qp/Qs ratio of ≥1.5:1, history of para-
doxical embolism, and the presence of symptoms such as 
dyspnea or palpitations in patients with smaller shunts. 
Detailed medical history, physical examination, and an 
electrocardiogram were obtained, and the morphology 
of the ASD was assessed by transthoracic echocardiog-
raphy and TEE prior to the intervention. If the size and 
morphology of the secundum ASD precluded the use of 
a percutaneous device, surgical repair was recommended 
and patients were not included in the registry. Specifi-
cally, if stretched defect size was ≥36  mm, if there was 
lack of adequate atrial septal rims to permit stable device 
deployment, especially towards the aortic root, or if the 
defect was too close to the AV valves, the coronary sinus, 
or the vena cava (Webb and Gatzoulis 2006), percutane-
ous closure was not attempted. The study was carried 
out in compliance with the Helsinki Declaration and 
approved by the local ethics committee (Kantonale Ethik-
kommission Zürich). All patients gave written informed 
consent.
Hemodynamics and shunt calculations
In about half of the patients, right heart catheterization 
was performed to obtain complete hemodynamic assess-
ment and oxygen saturations in the right heart chambers 
and the pulmonary artery, with simultaneous left heart 
catheterization being performed for shunt quantification 
by oximetry according to the Fick formula (Miller et  al. 
1974). In patients >65 years of age, transient ASD occlu-
sion with simultaneous measurement of left sided filling 
pressures was performed to exclude hemodynamically 
relevant left ventricular diastolic dysfunction or restric-
tive disease (Gruner et al. 2012).
Selection of large or small closure devices
In order to choose the appropriate device size, ASD 
diameter was determined in all patients before defect 
closure using intracardiac echocardiography (19  % of 
patients), fluoroscopy after occlusion of the defect with a 
sizing balloon (4 % of patients), or both sizing techniques 
(77  % of patients). ASD closure devices were selected 
on the basis of these measurements and ASD morphol-
ogy. For analysis, patients were assigned to two groups 
receiving either a large or small device. The large device 
group included patients receiving the following clo-
sure devices: Amplatzer Septal Occluder, waist diameter 
≥26 mm (n = 32, St. Jude Medical, St. Paul, MN, USA); 
Amplatzer Multi-Fenestrated Septal Occluder Cribri-
form, disc diameter 35 mm (n = 6, St. Jude Medical); and 
Solysafe Septal Occluder, waist diameter ≥25 mm (n = 4, 
Swissimplant, Solothurn, Switzerland). The small device 
group included patients receiving the following implants: 
Amplatzer Septal Occluder, waist diameter ≤24  mm 
(n = 54, St. Jude Medical); Amplatzer Multi-Fenestrated 
Septal Occluder Cribriform, disc diameter 25 mm (n = 3, 
St. Jude Medical); Amplatzer PFO Occluder, right atrial 
disc diameter 25 mm (n = 5, St. Jude Medical); Solysafe 
Septal Occluder, waist diameter ≤20  mm (n =  7, Swis-
simplant); and Helex Septal Occluder, device diameter 
25  mm (n =  1, Gore Medical, Flagstaff, AZ, USA). The 
criteria for device selection at our institution changed 
over time based on availability and current knowledge 
about efficacy and safety profiles.
Transcatheter ASD closure
Device implantation was performed under fluoro-
scopic guidance and routine intracardiac echocardi-
ography monitoring as described (Greutmann et  al. 
2009; Gruner et  al. 2012). During the procedure, stand-
ard heparin (70  IU/kg) was administered intravenously. 
Cefuroxim (1.5  g intravenously) was used for antibiotic 
prophylaxis prior to as well as 8 and 16 h after the inter-
vention. Antithrombotic regimen consisted of clopi-
dogrel (600 mg loading dose followed by 75 mg daily) for 
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3  months along with acetylsalicylic acid (100  mg daily) 
for 6  months. Endocarditis prophylaxis was recom-
mended for 6 months after ASD closure.
Follow‑up
Six months after ASD closure patient history was obtained, 
and a clinical examination, electrocardiography, and 
assessment of the closure device by TEE were performed. 
For detection of residual shunts Color Doppler imaging 
and intravenous administration of agitated saline was used 
during TEE. The presence of a significant residual shunt 
was diagnosed if >20 microbubbles crossed from the right 
to the left atrium within the first three cardiac cycles from 
right-sided contrast opacification while patients were per-
forming a Valsalva maneuver. Follow-up was completed 
in 107 out of 112 patients (96 %), which were included in 
subsequent analyses. Complete follow-up was unavailable 
in 1 patient who received a large closure device (Amplatzer 
Septal Occluder), and in 4 patients with small closure 
devices (3 Amplatzer Septal Occluders and 1 Amplatzer 
PFO Occluder), because they withdrew consent for either 
undergoing TEE or any follow-up examination.
Efficacy and safety outcomes
The primary efficacy outcome was defined as successful 
transcatheter ASD closure achieved by a single interven-
tion, confirmed by lack of a significant shunt detectable 
by TEE at 6-month follow-up. Secondary efficacy out-
comes included need of a repeat transcatheter ASD clo-
sure intervention, referral for surgical ASD closure due 
to failure of transcatheter closure, and presence of any 
residual shunt detected by TEE. In addition, functional 
status according to the NYHA classification was assessed 
at baseline and 6  months after the closure procedure. 
The primary safety outcome at 6-month follow-up was 
a composite of device embolization, new-onset atrial 
arrhythmia, and major bleeding defined as Type 2 or 
greater according to the BARC definition (Mehran et al. 
2011). Secondary safety outcomes included the individ-
ual components of the primary safety outcome, as well as 
all-cause mortality.
Statistical analyses
The distribution of continuous variables was assessed 
by D’Agostino and Pearson omnibus normality test. 
Data with significant deviation from normal distribu-
tion were analyzed by the nonparametric Mann–Whit-
ney test and are expressed as median and inter-quartile 
range. Normally distributed data were analyzed by the 
unpaired Student’s t test and are given as mean ± stand-
ard deviation. Categorical data were analyzed by Fisher’s 
exact test or Chi square test, as appropriate. Kaplan–
Meier estimates of event rates were compared between 
intervention groups with the use of the log-rank test. 
All analyses were performed using Prism version 5.0 for 
Macintosh (GraphPad Software, San Diego, CA, USA). p 
values <0.05 were considered significant.
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